 DELRAY BEACH, Fla., May 12, 2021 GLOBE NEWSWIRE -- AzurRx BioPharma, Inc. NASDAQ: AZRX, AzurRx or the Company, a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal GI diseases, today announced that AzurRx SAS, its wholly-owned subsidiary in France, has received approximately 459,000 Euros 550,000 U.S. in non-dilutive funding in research tax credits from the French government for its 2020 CIR French Research Tax Credit. 